Stay updated on PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.

Latest updates to the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference1.0%
- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check39 days agoChange DetectedThe web page has been updated to version 2.15.0 from version 2.14.4, indicating a revision in the content. The phrase 'Here’s how you know' has been modified to 'Here's how you know', which does not significantly alter the core content.SummaryDifference1.0%
- Check46 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check89 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check104 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
Stay in the know with updates to PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.